Lv4
620 积分 2025-04-11 加入
Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis
8小时前
待确认
Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024
21天前
已完结
Association between metabolic multimorbidity and the risk of cardiovascular disease, kidney disease, and mortality: longitudinal evidence from CHARLS (2011–2020)
28天前
已完结
Evaluation of statin-induced muscle and liver adverse drug reactions in the Chinese population: a retrospective analysis of clinical trial data from 1992 to 2023
1个月前
已完结
The LDL cumulative exposure hypothesis: evidence and practical applications
1个月前
已完结
Combination lipid-lowering therapy as first-line strategy in very high-risk patients
1个月前
已完结
Lipid-lowering drug therapy for reducing cardiovascular risk in diabetes. A clinical view of the Cardiovascular Disease Working Group of the Spanish Diabetes Society
1个月前
已完结
Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study
2个月前
已完结
Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease
3个月前
已完结
Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD)
3个月前
已完结
皖公网安备34019202002308
